Merrimack Pharmaceuticals Announces Timing of Third Quarter 2013 Investor Conference Call
October 29, 2013 16:30 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Oct. 29, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Third Quarter 2013 Investor Conference Call and webcast...
Merrimack Pharmaceuticals to Present Preclinical Data at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 15, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Oct. 15, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present preclinical research on two novel potential cancer therapies,...
Merrimack Pharmaceuticals Completes Enrollment of Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer
October 01, 2013 17:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Oct. 1, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in the second cohort of a two-cohort...
An Analysis of Cellular Networks to Predict Drug Response in Breast Cancer Lines Published in Science Signaling
September 20, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Sept. 20, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Science Signaling will publish the research article "Profiles of Basal and...
Merrimack to Present at the Morgan Stanley Global Healthcare Conference
September 03, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Morgan Stanley...
Merrimack Reaches Patient Enrollment Goal in the Phase 3 NAPOLI-1 Study of MM-398 in Late Stage Pancreatic Cancer
August 28, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Aug. 28, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the enrollment goal has been reached in the NAPOLI-1 trial. NAPOLI-1 is a...
Study of Novel Nanoliposomal Irinotecan (MM-398) in Late Stage Pancreatic Cancer Published in British Journal of Cancer
August 22, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Aug. 22, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the British Journal of Cancer has published the paper "A Multinational Phase 2...
Merrimack Pharmaceutical's MM-111 Granted Orphan Drug Status by FDA For Treatment of Advanced Gastric and Esophageal Cancers
August 13, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has...
Merrimack Reports Second Quarter 2013 Financial Results
August 08, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2013 Investor Conference Call
July 25, 2013 16:30 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 25, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Second Quarter 2013 Investor Conference Call and...